# EDGAR Filing Document

**Accession Number:** 0000895464
**File Stem:** 0001640334-25-000984
**Filing Date:** 2025-6
**Character Count:** 13212
**Document Hash:** 70b9d56cce7959a3e030aa7c2e55a8fe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-25-000984.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001640334-25-000984

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Yubo International Biotech Ltd
- **CENTRAL INDEX KEY:** 0000895464
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 113074326
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-52079
- **FILM NUMBER:** 251019025

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 (010) 6615-5141

**MAIL ADDRESS:**
- **STREET 1:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAGNA LAB INC
- **DATE OF NAME CHANGE:** 19940722
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Boao Biotech Ltd
- **CENTRAL INDEX KEY:** 0001841399

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** C/O YUBO INTERNATIONAL BIOTECH LIMITED
- **STREET 2:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** XICHENG DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 010 6615 5141

**MAIL ADDRESS:**
- **STREET 1:** C/O YUBO INTERNATIONAL BIOTECH LIMITED
- **STREET 2:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** XICHENG DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 00000

## Exhibit 99.1

**Exhibit Information** 

**99.1** **Joint Filing Agreement, dated June 3, 2025, by and between the Reporting Persons** 

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Class A Common Stock, par value $0.001 per share, of Yubo International Biotech Limited has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), apply to each of them.

This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Exchange Act.

This joint filing agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G/A as to any of the undersigned upon such person giving written notice thereof to each of the other persons party hereto, at the principal office thereof.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Date: June 3, 2025

---

| | |
|:---|:---|
| Boao Biotech Limited | Boao Biotech Limited |
| By: | /s/ Yulin Cao |
|  | Name: Yulin Cao |
|  | Title: Sole Director |
| /s/ Yulin Cao | /s/ Yulin Cao |
| YULIN CAO | YULIN CAO |

---

**NAME**: null

**TYPE**: SCHEDULE 13G

**DESCRIPTION**: null

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Yubo International Biotech Ltd

**Title of Class of Securities:** Class A Common Stock, $0.001 par value

**CUSIP Number:** 988366100

**Date of Event Which Requires Filing of this Statement:** 01/25/2024

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Boao Biotech Ltd | Names of Reporting Persons<br>Boao Biotech Ltd |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>D8 | Citizenship or Place of Organization<br>D8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>19927660.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>19927660.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>19927660.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>19927660.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>16.6% | Percent of Class Represented by Amount in Row (9)<br>16.6% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** (1) This percentage is based on 119,816,343 shares of Class A Common Stock outstanding as of May 13, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 13, 2025.

---

| 1. | Names of Reporting Persons<br>CAO YULIN | Names of Reporting Persons<br>CAO YULIN |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>19927660.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>19927660.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>19927660.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>19927660.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>16.6% | Percent of Class Represented by Amount in Row (9)<br>16.6% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** (1) This percentage is based on 119,816,343 shares of Class A Common Stock outstanding as of May 13, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 13, 2025.

---

**Item 1(a). Name of Issuer:**
Yubo International Biotech Ltd

**Item 1(b). Address of Issuer's Principal Executive Offices:**
Room 1102, Building 2, 10 Chaoyang Park, South Road, Chaoyang District, Beijing, CHINA, 100026.

**Item 2(a). Name of Person Filing:**
This Schedule 13G (this "13G") is being filed jointly by Boao Biotech Limited, a British Virgin Islands limited liability company ("Boao"), and Mr. Yulin Cao, an individual (together with Boao, the "Reporting Persons").

The securities reported in this 13G are held directly by Boao.  Mr. Yulin Cao is the sole Director of Boao, and as such, Yulin Cao may be deemed to have voting and investment power over such securities held by Boao.  Mr. Yulin Cao disclaims beneficial ownership of such securities for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his indirect pecuniary interest therein, if any, and this 13G shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 13(d) or 13(g) of the Exchange Act or for any other purposes.

The Reporting Persons have previously entered into a Joint Filing Agreement, dated June 3, 2025, which is attached hereto as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file jointly this 13G and any subsequent amendments hereto in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

**Item 2(b). Address of Principal Business Office:**
C/O Wickham's Cay II, P.O. Box 2221
Road Town, Tortola, British Virgin Islands

**Item 2(c). Citizenship:**
Boao is a British Virgin Islands limited liability company.
Mr. Yulin Cao is a citizen of China.

**Item 2(d). Title of Class of Securities:**
Class A Common Stock, $0.001 par value

**Item 2(e). CUSIP Number:**
988366100

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Boao: 19,927,660
Yulin Cao: 19,927,660

**(b) Percent of class:**

Boao: 16.6%
Yulin Cao: 16.6%
This percentage is based on 119,816,343 shares of Class A Common Stock outstanding as of May 13, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 13, 2025.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Boao: 0
Yulin Cao: 0

**(ii) Shared power to vote or to direct the vote:**

Boao: 19,927,660
Yulin Cao: 19,927,660

**(iii) Sole power to dispose or to direct the disposition of:**

Boao: 0
Yulin Cao: 0

**(iv) Shared power to dispose or to direct the disposition of:**

Boao: 19,927,660
Yulin Cao: 19,927,660

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Boao Biotech Ltd**

**Date:** 06/03/2025

**By:** /s/ Yulin Cao

**Name & Title:** Sole Director

**CAO YULIN**

**Date:** 06/03/2025

**By:** /s/ Yulin Cao

**Name & Title:** Yulin Cao